Ultragenyx Pharmaceutical Inc (RARE) was Initiated by Piper Jaffray to “Overweight” and the brokerage firm has set the Price Target at $70. Piper Jaffray advised their investors in a research report released on Jul 7, 2016.
Many Wall Street Analysts have commented on Ultragenyx Pharmaceutical Inc. Ultragenyx Pharmaceutical Inc was Initiated by BofA/Merrill to “Buy” on Jun 28, 2016. Shares were Reiterated by Wedbush on May 10, 2016 to “Outperform” and Lowered the Price Target to $ 92 from a previous price target of $99 .
On the company’s financial health, Ultragenyx Pharmaceutical Inc reported $-1.35 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on May 9, 2016. Analyst had a consensus of $-1.23.During the same quarter in the previous year, the company posted $-0.63 EPS.
Ultragenyx Pharmaceutical Inc closed down -1.72 points or -3.33% at $49.99 with 6,73,933 shares getting traded on Tuesday. Post opening the session at $51, the shares hit an intraday low of $49.06 and an intraday high of $51 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Jun 21, 2016, Sunil Agarwal (Chief Medical Officer) sold 650 shares at $54.16 per share price. According to the SEC, on May 18, 2016, Emil D Kakkis (President & CEO) sold 20,000 shares at $60.74 per share price. On Dec 18, 2015, Theodore Alan Huizenga (Controller and PAO) sold 1,500 shares at $110.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification acquisition development and commercialization of products for the treatment of rare and ultra-rare diseases with a focus on serious debilitating genetic diseases. Its pipeline consists of two product categories: biologics including a monoclonal antibody and enzyme replacement therapies and small-molecule substrate replacement therapies. Its products are KRN23 (UX023) rhGUS (UX003) rhPPCA (UX004) Triheptanoin (UX007) and SA-ER (UX001). KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. rhGUS is an intravenous (IV) enzyme replacement therapy for the treatment of mucopolysaccharidosis 7. rhPPCA is an enzyme replacement therapy for galactosialidosis. Triheptanoin is a medium odd-chain triglyceride of seven-carbon fatty acids. SA-ER is for the treatment of hereditary inclusion body myopathy (HIBM).